Solid Biosciences (SLDB) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free SLDB Stock Alerts $9.75 -0.64 (-6.16%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 2, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 13, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest Up 49.8% in MarchSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 920,900 shares, a growth of 49.8% from the March 15th total of 614,900 shares. Approximately 3.1% of the company's stock are short sold. Based on an average daily trading volume, of 362,300 shares, the days-to-cover ratio is presently 2.5 days.April 10, 2024 | seekingalpha.comBuy Solid Biosciences: Unpacking Its Main Value DriverApril 3, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | markets.businessinsider.comSolid Biosciences: FDA Grants Rare Pediatric Disease Designation For SGT-003April 1, 2024 | globenewswire.comSolid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003March 28, 2024 | msn.comWilliam Blair starts Solid Biosciences at outperformMarch 28, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by AnalystsSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month price objectiMarch 28, 2024 | marketbeat.comSolid Biosciences' (SLDB) Outperform Rating Reaffirmed at William BlairWilliam Blair restated an "outperform" rating on shares of Solid Biosciences in a research report on Thursday.March 27, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Reaches New 1-Year High at $14.99Solid Biosciences (NASDAQ:SLDB) Sets New 1-Year High at $14.99March 27, 2024 | finance.yahoo.comSolid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumMarch 24, 2024 | finance.yahoo.comSLDB Apr 2024 7.500 putMarch 19, 2024 | markets.businessinsider.comCautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid BiosciencesMarch 18, 2024 | marketbeat.comBarclays Increases Solid Biosciences (NASDAQ:SLDB) Price Target to $21.00Barclays raised their target price on Solid Biosciences from $8.00 to $21.00 and gave the company an "overweight" rating in a report on Monday.March 18, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Thursday.March 18, 2024 | markets.businessinsider.comSolid Biosciences (SLDB) Gets a Buy from BarclaysMarch 16, 2024 | finance.yahoo.comSLDB Sep 2024 17.500 callMarch 15, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Receives New Coverage from Analysts at CitigroupCitigroup started coverage on Solid Biosciences in a research note on Friday. They set a "buy" rating and a $16.00 price objective on the stock.March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Solid Biosciences on Promising Pipeline and Financial StabilityMarch 14, 2024 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Upgraded to Overweight at Piper SandlerPiper Sandler upgraded Solid Biosciences from a "neutral" rating to an "overweight" rating and raised their target price for the company from $8.00 to $20.00 in a research report on Thursday.March 13, 2024 | finanznachrichten.deSolid Biosciences Inc.: Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsMarch 13, 2024 | markets.businessinsider.comSolid Biosciences Stock Drops 4% Due To Wider Loss In Q4March 13, 2024 | msn.comSolid Biosciences, Cue Biopharma, Annexon among healthcare moversMarch 13, 2024 | globenewswire.comSolid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsMarch 11, 2024 | realmoney.thestreet.comSolid Biosciences price target raised by $7 at H.C. Wainwright, here's whyMarch 11, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB)March 7, 2024 | msn.comSolid Biosciences signs agreement with Armatus Bio for AAV-SLB101March 7, 2024 | finance.yahoo.comSolid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDMarch 1, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest UpdateSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 607,300 shares, a growth of 41.8% from the January 31st total of 428,300 shares. Currently, 2.0% of the company's shares are sold short. Based on an average daily volume of 475,200 shares, the short-interest ratio is presently 1.3 days.February 22, 2024 | benzinga.comSolid Biosciences Stock (NASDAQ:SLDB) Insider TradesFebruary 22, 2024 | benzinga.comSolid Biosciences Stock (NASDAQ:SLDB), Short Interest ReportFebruary 18, 2024 | msn.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 17, 2024 | finance.yahoo.comSLDB Mar 2024 10.000 putFebruary 6, 2024 | markets.businessinsider.comHold Rating on Solid Biosciences Amid Gene Therapy Developments and Regulatory MilestonesJanuary 23, 2024 | investing.comSolid Biosciences LLC (SLDB)January 16, 2024 | finanznachrichten.deSolid Biosciences Inc.: Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003January 16, 2024 | markets.businessinsider.comSolid Biosciences Granted FDA ODD For SGT-003January 16, 2024 | finance.yahoo.comSolid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003January 15, 2024 | finance.yahoo.comSolid Biosciences (SLDB) Rises 271% in 3 Months: Here's WhyJanuary 14, 2024 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest Up 21.8% in DecemberSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 247,800 shares, an increase of 21.8% from the December 15th total of 203,400 shares. Based on an average trading volume of 590,500 shares, the short-interest ratio is presently 0.4 days. Currently, 1.5% of the company's shares are short sold.January 12, 2024 | marketbeat.comPerceptive Advisors Llc Acquires 3,410,713 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) StockSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) Director Perceptive Advisors Llc bought 3,410,713 shares of the company's stock in a transaction that occurred on Thursday, January 11th. The stock was bought at an average cost of $5.53 per share, for a total transaction of $18,861,242.89. Following the completion of the transaction, the director now directly owns 6,833,539 shares in the company, valued at $37,789,470.67. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.January 12, 2024 | msn.comSolid Biosciences wins FDA orphan status for muscle disorder therapyJanuary 11, 2024 | marketbeat.comInsider Selling: Solid Biosciences Inc. (NASDAQ:SLDB) CFO Sells 3,935 Shares of StockSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CFO Kevin Tan sold 3,935 shares of the firm's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $8.20, for a total transaction of $32,267.00. Following the completion of the transaction, the chief financial officer now owns 9,308 shares in the company, valued at $76,325.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.January 8, 2024 | marketbeat.comTrading was temporarily halted for "SLDB" at 09:01 AM with a stated reason of "LULD pause."January 8, 2024 | msn.comSolid Biosciences raises $109M through private placementJanuary 8, 2024 | finance.yahoo.comSolid Biosciences Announces $109 Million Private PlacementJanuary 4, 2024 | finance.yahoo.comSolid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceDecember 21, 2023 | benzinga.comSolid Biosciences Stock (NASDAQ:SLDB), Analyst Ratings, Price Targets, PredictionsDecember 16, 2023 | msn.comSolid Biosciences (SLDB) Price Target Increased by 6.67% to 7.34December 9, 2023 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address How to Make 100X on the AI Boom (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs SLDB Media Mentions By Week SLDB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLDB News Sentiment▼0.440.57▲Average Medical News Sentiment SLDB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLDB Articles This Week▼11▲SLDB Articles Average Week Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Ocugen News Today Tourmaline Bio News Today Black Diamond Therapeutics News Today TScan Therapeutics News Today Aura Biosciences News Today Replimune Group News Today Tenaya Therapeutics News Today Alvotech News Today Fate Therapeutics News Today Lexeo Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLDB) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportGuard Against the Coming Financial UpheavalPorter & CompanyDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
